Add:4th Floor,Binhai New City Headquarters,Changle City,Fujian,China
Mobile:173 4640 3193
Copyright © 2018 Fujian Gospel Precision Medicine Development Co., Ltd. All Rights Reserved. 闽ICP备18011183号-1
Fujian Province Precision Medicine Industry Innovation Center starts in Fuzhou Binhai New City
On the morning of April 1, Fujian Precision Medicine Industry Innovation Center officially started construction in Binhai New City, Fuzhou. At the same time, it held the signing ceremony of the Fuzhou City Precision Medicine Industry Development Forum and project.
The event was sponsored by the Fuzhou New District Administrative Committee. The Fujian Provincial Precision Medicine Industrial Innovation Center started construction and is a key project invested and built by Fujian Fushao Precision Medicine Development Co., Ltd. in Binhai New City, with a total investment of nearly 1.5 billion yuan. 120 acres, with a total construction area of 200,000 square meters, is planned to be completed within two years. It mainly undertakes the introduction of advanced medical R&D talents and units, and conducts clinical applications and industrial transformation of precision medical research such as genetics, oncology genomics, biological big data, precision immunotherapy, and tumor precise medical technology.
After the start of the construction ceremony, He Yuan Biotech (Shanghai) Co., Ltd., Fellow of the Royal Academy of Sciences, Professor Mai Dehua of the University of Toronto Professor of Medical Biophysics and Immunology, and Dr. Li Yong, the Special Expert of the Central Organization Department “Thousand People Program” Thirteen other units and teams signed a contract with Fuzhou Precision Medicine Development Co., Ltd. A total of 28 projects were launched in Fujian Province Precision Medicine Industry Innovation Center with a total valuation of approximately 12 billion. At the same time, seven strategic companies, namely the Sinopharm Group, the Hong Kong Bio-Pharmaceutical Innovation Association, the Taiwan Bio-industry Development Association, and the seven companies in the “Taiwan Three Areas,” signed a strategic cooperation agreement with Fusui Precision Medicine Development Co., Ltd.